                         SEQUENCE LISTING

<110>  Gilead Sciences, Inc.
 
<120>  Combination of a TLR8 Modulating Compound and Anti-HBV siRNA 
       Therapeutics

<130>  052838-583001WO

<140>  Herewith
<141>  2022-05-12

<150>  US 63/336,709
<151>  2022-04-29

<150>  US 63/188,339
<151>  2021-05-13

<160>  2     

<170>  PatentIn version 3.5

<210>  1
<211>  21
<212>  RNA
<213>  Artificial sequence

<220>
<223>  Synthetic polypeptide

<400>  1
ugugaagcga agugcacacu u                                                 21


<210>  2
<211>  19
<212>  RNA
<213>  Artificial sequence

<220>
<223>  Synthetic polypeptide

<400>  2
gugugcacuu cgcuucaca                                                    19


